Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
As the final cohort in the Phoenix trial reads out positively for bardoxolone the stage is set for pivotal results and a decision by Abbvie.